National screening committee
The UK national body that advises on screening programmes within the NHS.
The UK national body that advises on screening programmes within the NHS.
We are needs-led because we assess the important questions and the priority they should be answered in. We actively ensure that our programmes meet the needs of decision makers. We ensure that we are needs-led throughout the funding pipeline, by actively assessing need and priority for all funding streams.
National Health Service: government-funded medical and health care services that everyone living in the UK can use without being asked to pay the full cost of the service.
NHS research is research carried out in the NHS or funded by the NHS. This includes research that takes place in local hospitals or GP surgeries, and larger studies commissioned by the NHS at a national level. For example a study based in a GP surgery looking at people’s experience of long-term chronic pain or a randomised controlled trial to look at the best treatment for people with bowel cancer.
The National Institute for Health and Clinical Excellence recommends which treatments should be provided by the NHS. NICE makes extensive use of evidence generated by the NIHR programmes.
The NIHR Academy is responsible for development and coordination of NIHR academic training, career development and research capacity development.
The NIHR BioResource for Translational Research in Common and Rare Diseases (NIHR BioResource) is a national resource of patients and members of the general population who have volunteered to be called up for research based on their genotype and phenotype.
The NIHR Health Informatics Collaborative (HIC) has been set up to deliver high quality data in five key therapeutic areas across five of the largest university hospital trusts, each of which hosts a BRC.
The NIHR National Biosample Centre provides high throughput and high quality biosample processing, storage and retrieval services to for NIHR-supported research, and research funded by partners of the Department of Health, such as the MRC, charities and industry.
A trial designed to determine whether the effect of a new treatment is not worse than a standard treatment by more than a pre-specified amount.